Genes And Gene Products As Immunoadjuvants
Genes And Gene Products As Immunoadjuvants
批准号:
10274157
负责人:
Steven Holland
金额:
$158.04万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
Acquired Immunodeficiency SyndromeAdultAffectBronchiectasisChildCoccidioidomycosisCryptococcosisCutaneousCystic FibrosisCytokine ReceptorsDefectDevelopmentDiseaseDisease ResistanceDrug resistanceDysmyelopoietic SyndromesEpidemiologyEpigenetic ProcessEpithelialEpitheliumEtiologyFunctional disorderGenesGeneticGenus MycobacteriumHistoplasmosisHost DefenseHumanImmuneImmune responseImmunityImmunobiologyImmunocompromised HostImmunologic AdjuvantsIn VitroInfectionInflammatoryInnate Immune ResponseInterferon Type IIInterleukin-12Interleukin-17LeadLesionLungLung diseasesLymphocyteMalignant NeoplasmsMicrobeMicrobiologyMutationMycobacterium InfectionsMycobacterium tuberculosisMycosesNatureOrganismOutcomePathogenesisPathway interactionsPatientsPhagocytesPredispositionProductionReceptor SignalingRegulationRoleSalmonellaSignal PathwaySyndromeTNF geneTherapeuticTuberculosiscytokinecytokine therapydrug-sensitiveexperimental studyfungusgene productinterestinterleukin-23macrophagemycobacterialnon-tuberculosis mycobacterianovel therapeutic interventionpathogenresponsetuberculosis treatment
中文摘要
我们致力于先天性和获得性综合征的识别、描述和治疗,这些综合征增加了对分枝杆菌和细胞内真菌感染的易感性,包括球孢子菌病。我们感兴趣的综合征主要影响吞噬细胞,最明显的是对非结核分枝杆菌的易感性增加。这些微生物被认为是重要的病原体,只有在免疫受损的宿主中才有。因此,我们试图找出那些以前没有公认的免疫损害形式的患者,他们患有这些感染,然后确定他们的易感性。通过这种方式,我们已经确定和表征了参与控制分枝杆菌和其他细胞内病原体的途径,如沙门氏菌病、组织胞浆菌病、球孢子菌病、隐球菌病以及非结核分枝杆菌。我们已经发现的异常集中在巨噬细胞/淋巴细胞相互作用导致干扰素-γ、IL-12、IL-23、IL-17和肿瘤坏死因子的产生或应答。此外,调节对肿瘤坏死因子反应的通路与干扰素伽马信号通路重叠,并已被证明在这些感染的患者中受到损害。对这些“自然实验”的研究突出了巨噬细胞/淋巴细胞相互作用在控制分枝杆菌和包括真菌在内的其他细胞内病原体方面的关键作用。这些观察结果使我们探索了细胞因子疗法和细胞因子修饰疗法,这些疗法可能在结核病的治疗中有更广泛的应用。在过去的一年里,我们通过对肺外真菌患者的研究,继续关注分枝杆菌感染中炎性基因调控的重要性。我们已经在组织胞浆菌病、球孢子菌病和分枝杆菌病患者中发现了细胞因子受体和信号的异常。我们还关注了单核细胞减少和分枝杆菌病综合征(MonoMAC),它是由GATA2突变引起的,也容易发生骨髓异常增生和恶性肿瘤。
识别这些重叠通路中的基因有助于我们了解细胞内感染的控制,并应引导我们开发更有针对性和更成功的治疗方法。这些感染在许多方面与艾滋病的感染有重叠。
英文摘要
We are working on the identification, description, and treatment of congenital and acquired syndromes of increased susceptibility to mycobacterial and intracellular fungal infections, including coccidioidomycosis. The syndromes in which we are interested primarily affect the phagocytes, and are most apparent in the increased susceptibility to nontuberculous mycobacteria. These organisms are thought to be important pathogens only in the immunocompromised host. Therefore, we have sought to identify patients without previously recognized forms of immunocompromise who have these infections and then determine the nature of their susceptibility. In this way we have identified and characterized the pathways involved in the control of mycobacteria and other intracellular pathogens, such as Salmonella, histoplasmosis, coccidioidomycosis, and cryptococcosis as well as nontuberculous mycobacteria. The abnormalities we have already identified center around macrophage/lymphocyte interactions leading to the production of or response to interferon gamma, IL-12, IL-23, IL-17 and tumor necrosis factor. In addition, the pathways regulating the response to tumor necrosis factor overlap with the interferon gamma signaling pathways and have been shown to be lesioned in patients with these infections. The study of these "experiments of nature" highlights the critical role of the macrophage/ lymphocyte interaction in control of mycobacteria and other intracellular pathogens, including fungi. These observations have led us to explore cytokine therapies and cytokine modifying therapies that may have broader applications to the treatment of tuberculosis. Over the last year we have continued our focus on the importance of the regulation of inflammatory genes in mycobacterial infections through the study of patients with extrapulmonary fungi. We have identified abnormalities in cytokine receptors and signaling in those with histoplasmosis and coccidioidomycosis as well as mycobacteria. We have also focused on the syndrome of monocytopenia and mycobacterial disease (MonoMAC), which is due to mutations in GATA2 and also predisposes to myelodysplasia and malignancy.
The identification of genes in these overlapping pathways has helped us understand the control of intracellular infection and should lead us to the development of more focused and more successful therapeutics. These infections overlap in many ways with those seen in AIDS.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Tuberculosis Imaging Program
-
批准号:10274165
-
项目类别:
-
资助金额:$232.01万
-
财政年份:--
-
负责人:Steven Holland
-
依托单位:
Genes And Gene Products As Immunoadjuvants
-
批准号:8745330
-
项目类别:
-
资助金额:$204.28万
-
财政年份:--
-
负责人:Steven Holland
-
依托单位:
Transgenic Animal Models Of Human Immune Defects
-
批准号:9567417
-
项目类别:
-
资助金额:$100.96万
-
财政年份:--
-
负责人:Steven Holland
-
依托单位:
Rituximab for Anticytokine Autoantibody-Associated Syndromes
-
批准号:10712564
-
项目类别:
-
资助金额:$27.61万
-
财政年份:--
-
负责人:Steven Holland
-
依托单位:
International Research in Thailand
-
批准号:8336280
-
项目类别:
-
资助金额:$4.35万
-
财政年份:--
-
负责人:Steven Holland
-
依托单位:
International Research in Thailand
-
批准号:7732717
-
项目类别:
-
资助金额:$5.52万
-
财政年份:--
-
负责人:Steven Holland
-
依托单位:
International Research in Thailand
-
批准号:10928529
-
项目类别:
-
资助金额:$28.59万
-
财政年份:--
-
负责人:Steven Holland
-
依托单位:
Transgenic Animal Models Of Human Immune Defects
-
批准号:8156872
-
项目类别:
-
资助金额:$201.65万
-
财政年份:--
-
负责人:Steven Holland
-
依托单位:
International Research in Thailand
-
批准号:10274158
-
项目类别:
-
资助金额:$21.55万
-
财政年份:--
-
负责人:Steven Holland
-
依托单位:
Transgenic Animal Models Of Human Immune Defects
-
批准号:10274156
-
项目类别:
-
资助金额:$158.04万
-
财政年份:--
-
负责人:Steven Holland
-
依托单位:
Role of reactive oxygen species and the microbiome in intestinal barrier homeostasis
-
批准号:10712565
-
项目类别:
-
资助金额:$10.57万
-
财政年份:--
-
负责人:Steven Holland
-
依托单位:
Centralized Sequencing Program
-
批准号:10712580
-
项目类别:
-
资助金额:$423.95万
-
财政年份:--
-
负责人:Steven Holland
-
依托单位:
Genes And Gene Products As Immunoadjuvants
-
批准号:8336089
-
项目类别:
-
资助金额:$160.85万
-
财政年份:--
-
负责人:Steven Holland
-
依托单位:
Transgenic Animal Models Of Human Immune Defects
-
批准号:8336088
-
项目类别:
-
资助金额:$168.03万
-
财政年份:--
-
负责人:Steven Holland
-
依托单位:
Rituximab for Anticytokine Autoantibody-Associated Syndromes
-
批准号:10928530
-
项目类别:
-
资助金额:$28.59万
-
财政年份:--
-
负责人:Steven Holland
-
依托单位:
International Research in Thailand
-
批准号:8157056
-
项目类别:
-
资助金额:$5.5万
-
财政年份:--
-
负责人:Steven Holland
-
依托单位:
Genes And Gene Products As Immunoadjuvants
-
批准号:8156873
-
项目类别:
-
资助金额:$181.86万
-
财政年份:--
-
负责人:Steven Holland
-
依托单位:
Anticytokine Autoantibodies in COVID-19
-
批准号:10274160
-
项目类别:
-
资助金额:$4.42万
-
财政年份:--
-
负责人:Steven Holland
-
依托单位:
International Research in Thailand
-
批准号:8946455
-
项目类别:
-
资助金额:$57.57万
-
财政年份:--
-
负责人:Steven Holland
-
依托单位:
International Research in Thailand
-
批准号:7964706
-
项目类别:
-
资助金额:$12.69万
-
财政年份:--
-
负责人:Steven Holland
-
依托单位:
海外基金